Why Is Gilead Sciences Stock Trading Higher On Thursday?
Why Is Gilead Sciences Stock Trading Higher On Thursday?
Thursday, Gilead Sciences Inc (NASDAQ:GILD) shared topline results from an interim analysis of its Phase 3 PURPOSE 1 trial indicating its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, demonstrated 100% efficacy for the investigational use of HIV prevention in cisgender women.
吉利德科學股份有限公司（NASDAQ:GILD）週四公佈了其III期PURPOSE 1試驗中間分析的頂線結果，表明其每年兩次注射的HIV-1殼聚糖抑制劑lenacapavir在順性別女性投入使用的研究中表現出100％的功效。
PURPOSE 1 study met its key efficacy endpoints of the superiority of twice-yearly lenacapavir to once-daily oral Truvada (emtricitabine 200mg and tenofovir disoproxil fumarate 300mg; F/TDF) and background HIV incidence (bHIV).
PURPOSE 1研究實現了其兩個主要效力終點：兩年一次lenacapavir的優越性，相對於每日一次口服Truvada（200mg emtricitabine和300mg tenofovir disoproxil fumarate；F/TDF）和背景HIV發病率（bHIV）。
Based on these results, the independent Data Monitoring Committee (DMC) recommended that Gilead stop the blinded phase of the trial and offer open-label lenacapavir to all participants.
基於這些結果，獨立的數據監測委員會（DMC）建議吉利德停止試驗的盲目階段，併爲所有參與者提供開放標籤lenacapavir。
"With zero infections and 100% efficacy, twice-yearly lenacapavir has demonstrated its potential as an important new tool to help prevent HIV infections," said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences.
"在沒有感染和100％的功效的情況下，兩年一次的lenacapavir展示了它作爲一種重要的新工具來幫助預防HIV感染的潛力，"吉利德科學首席醫學官Merdad Parsey博士說。
There were 0 incident cases of HIV infection among women in the lenacapavir group (incidence 0.00 per 100 person-years).
lenacapavir組中的女性沒有發生HIV感染事件（發生率爲每100人年0.00）。
The results demonstrated the superiority of twice-yearly lenacapavir over bHIV (primary endpoint, incidence 2.41 per 100 person-years) and superiority of twice-yearly lenacapavir over once-daily Truvada (secondary endpoint), with p<0.0001 for both endpoints.
結果證明了在背景HIV發病率（主要終點，每年100人次發病率2.41）和兩年一次lenacapavir相對於每日一次Truvada（次要終點）方面，兩年一次lenacapavir的優越性，對於這兩個終點來說，p＜0.0001。
In the trial, lenacapavir was generally well-tolerated and no significant or new safety concerns were identified.
在試驗中，lenacapavir總體耐受性良好，沒有發現重大或新的安全問題。
HIV incidence in the Descovy group was numerically similar to that in the Truvada group and was not statistically superior to bHIV.
Descovy組中的HIV發病率與Truvada組類似，且在bHIV方面並未表現出統計學優越性。
Gilead expects results in late 2024/early 2025 from the program's other pivotal trial, PURPOSE 2, which is assessing twice-yearly lenacapavir for PrEP among cisgender men.
吉利德預計其該計劃的另一個關鍵性試驗PURPOSE 2將在2024年底/2025年初得出結果，該試驗評估順性別男性使用兩年一次的lenacapavir作爲PrEP。
Price Action: GILD shares are up 8% at $68.20 at last check Thursday.
股價表現：GILD股價週四最後一次交易時上漲8％至68.20美元。
Photo via Shutterstock
圖片來自shutterstock。
譯文內容由第三人軟體翻譯。